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Nicoletti-Carvalho JE, Lellis-Santos C, Yamanaka TS, Nogueira
TC, Caperuto LC, Leite AR, Anhê GF, Bordin S. MKP-1 mediates
glucocorticoid-induced ERK1/2 dephosphorylation and reduction in pan-
creatic -cell proliferation in islets from early lactating mothers. Am J
Physiol Endocrinol Metab 299: E1006–E1015, 2010. First published
September 21, 2010; doi:10.1152/ajpendo.00341.2010.—Maternal pan-
creatic islets undergo a robust increase of mass and proliferation
during pregnancy, which allows a compensation of gestational insulin
resistance. Studies have described that this adaptation switches to a
low proliferative status after the delivery. The mechanisms underlying
this reversal are unknown, but the action of glucocorticoids (GCs) is
believed to play an important role because GCs counteract the preg-
nancy-like effects of PRL on isolated pancreatic islets maintained in
cell culture. Here, we demonstrate that ERK1/2 phosphorylation
(phospho-ERK1/2) is increased in maternal rat islets isolated on the
19th day of pregnancy. Phospho-ERK1/2 status on the 3rd day after
delivery (L3) rapidly turns to values lower than that found in virgin
control rats (CTL). MKP-1, a protein phosphatase able to dephos-
phorylate ERK1/2, is increased in islets from L3 rats. Chromatin
immunoprecipitation assay revealed that binding of glucocorticoid
receptor (GR) to MKP-1 promoter is also increased in islets from L3
rats. In addition, dexamethasone (DEX) reduced phospho-ERK1/2
and increased MKP-1 expression in RINm5F and MIN-6 cells. Inhi-
bition of transduction with cycloheximide and inhibition of phospha-
tases with orthovanadate efficiently blocked DEX-induced downregu-
lation of phospho-ERK1/2. In addition, specific knockdown of
MKP-1 with siRNA suppressed the downregulation of phospho-
ERK1/2 and the reduction of proliferation induced by DEX. Alto-
gether, our results indicate that downregulation of phospho-ERK1/2 is
associated with reduction in proliferation found in islets of early
lactating mothers. This mechanism is probably mediated by GC-
induced MKP-1 expression.
mitogen-activated protein kinase phosphatase-1; extracellular signal-
regulated kinase 1/2; dual-specificity phosphatases; pregnancy; lacta-
tion
PREGNANCY IS HIGHLIGHTED AS A PHYSIOLOGICAL STATE in which
pancreatic -cells from maternal pancreatic islets undergo a
robust mass growth due to proliferation (41). Increasing pan-
creatic -cell mass is an adaptive event that allows the mater-
nal organism to meet the insulin demand and compensate
peripheral insulin resistance (31). Pregnancy-like changes in
pancreatic -cells, such as an increase in proliferation, can be
mimicked by treatment with prolactin (PRL) in cell culture
(11). The importance of PRL was further demonstrated in vivo,
since pancreatic islets from pregnant PRL receptor (/) mice
display reduced pancreatic -cell mass compared with preg-
nant wild-type mothers (24).
A singular feature of the metabolic adaptation during preg-
nancy is the rapid reversal that occurs after the delivery,
allowing the maternal organism to recover its nonpregnant
status (4, 38). Scaglia et al. (38) first demonstrated that mater-
nal pancreatic islets undergo a transient reduction in pancreatic
-cell proliferation as early as the 4th day postpartum. Impor-
tantly, this transient reduction in proliferation occurs despite
high levels of circulating PRL (27). Glucocorticoids (GCs) are
believed to account for this reversal because of its elevated
concentration during the end of pregnancy and because this
hormone is able to counteract PRL-induced -cell proliferation
in cell culture (44). However, the intracellular mechanism by
which this in vivo reversal occurs has not been settled.
The family of serine/threonine kinases known as extracellu-
lar signal-regulated kinases (ERKs) belongs to the mitogen-
activated protein kinases (MAPKs), a conserved family of
enzymes that regulate a large number of physiological pro-
cesses, including proliferation, differentiation, development,
stress responses, and apoptosis (12, 43). The isoforms p44/p42
(ERK1/2) are activated by phosphorylation on threonine and
tyrosine residues and are the main MAPKs involved in cell
proliferation (33). Because MAPK activities depend primarily
on tyrosine/threonine phosphorylation, dephosphorylation of
either residue inactivates these enzymes. This task can be
accomplished by three distinct families of phosphatases; the
major family involved in vertebrate MAPK signaling is com-
prised by the dual-specificity (Thr/Tyr) phosphatases (DUSPs),
also known as MAPK phosphatases (MKPs) (16). MKP-1, a
dual-specificity phosphatase known to dephosphorylate and
inactivate ERK1/2, is expressed in mouse pancreatic islets and
in -cell line MIN6 (32, 45).
We have demonstrated previously that islets isolated from
pregnant rats display increased ERK1/2 activity (1). To study
in more detail the involvement of ERK1/2 in postpregnancy
-cell remodeling, we evaluated the GC-dependent regulation
of ERK1/2 phosphorylation in early lactating rats and in -cell
lineages. We demonstrate presently that downregulation of
ERK1/2 phosphorylation in pancreatic islets from early lactat-
ing mothers correlates with the stimulation of MKP-1 by GC.
We also present data showing that the induction of MKP-1
expression in pancreatic -cells in vitro by GC is a mechanism
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underlying the reduction in pancreatic -cell proliferation and
ERK1/2 activity.
MATERIALS AND METHODS
Materials. The reagents, nitrocellulose membrane (0.45 mm), ap-
paratus for SDS-PAGE, and immunoblotting were obtained from
Bio-Rad (Richmond, CA). Tris, dithiothreitol, Tween-20, glycerol,
dexamethasone (DEX), and sodium orthovanadate were obtained
from Sigma Chemical (St. Louis, MO). RPMI-1640, Opti-MEM,
Lipofectamine 2000, fetal bovine serum (FBS), antibiotics, Trizol
reagent, and random primers were from Invitrogen (Carlsbad, CA).
Cycloheximide was purchased from Calbiochem (La Jolla, CA).
Bromodeoxyurudine (BrdU) Cell Proliferation Kit and EZ Chromatin
Immunoprecipitation (ChIP) Kit were from Millipore (Billerica, MA).
X-ray-sensitive films and chemicals were from IBF (Rio de Janeiro,
Brazil). Antibody against ERK1/2 (06-182) was from Upstate Bio-
technology (Lake Placid, NY), and anti-phospho-ERK1/2 Tyr (sc-
7383), anti-MKP-1 (sc-370), and anti-GR (M20 sc-1004) antibodies
and si-MKP-1 (sc-156118) or scrambled control siRNA (sc-37007)
were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti--actin
antibody (A5316) was from Sigma Chemical. PCR primers were
manufactured by Integrated DNA Technologies (Coralville, IA). GoTaq
DNA polymerase and ImProm-II reverse transcriptase were from Pro-
mega (Madison, WI). Brilliant SYBR Green qPCR MasterMix and
plastics were purchased from Agilent-Stratagene (La Jolla, CA). Rat
PRL was provided by the National Hormone and Pituitary Program of
the National Institute of Diabetes and Digestive and Kidney Diseases.
Animals and islet isolation. One male and two female rats were
housed together for 5 days. The presence of spermatozoa in the
vaginal wash indicated day 0 of gestation. Immediately after delivery,
the number of pups was adjusted to eight for each lactating mother.
Pregnant and lactating rats were euthanized at 19 days postcoitus
(P19) and 3 days postpartum (L3). Virgin age-matched rats were used
as the control group (CTL). Islets were isolated by collagenase
digestion, as described previously (9). All of the experiments involv-
ing animals were conducted in accordance with the guidelines of the
Brazilian College for Animal Experimentation. Our experiments were
approved by the Ethics Committee on Animal Use at the Institute of
Biomedical Sciences, University of Sao Paulo, Brazil.
Cells, growth conditions, and treatments. Rat RINm5F insulinoma
cell line was cultured in RPMI-1640 medium containing 11.1 mM
glucose, 10% FBS, and antibiotics (100 U/ml penicillin and 0.1 mg/ml
streptomycin). Early-passage MIN6 cells before passage 20 were also
used in this study. MIN6 cells were grown in RPMI-1640 containing
11.1 mM glucose, 10% FBS, and antibiotics, unless otherwise stated.
DEX was diluted in ethanol to a 10-mM stock solution. The same
amount of ethanol used in DEX-treated cells was added in control
cells. The activity of tyrosine phosphatases was inhibited by cell
pretreatment with 1.5 M sodium orthovanadate for 1 h. General
translation blockage was carried out with 40 g/ml of cycloheximide
1 h prior to DEX treatment. PRL treatment (500 ng/ml) was carried
out in RINm5F cells and lasted 3 days in either the absence or
presence of DEX (100 nM). When used for Western blot, PRL
treatment of RINm5F cells was performed in RPMI medium contain-
ing 10% FBS.
Transfection of MIN6 cells with small interference RNA (siRNA)
targeted to MKP-1 (si-MKP-1) or scrambled control siRNA were
performed as described previously (3, 35). Briefly, cells were washed
twice with serum- and glucose-free medium (Opti-MEM) and then
incubated with 1 ml of the same medium containing the siRNA (final
concentration of 80 nM) previously mixed with 2 l of Lipofectamine
2000. In parallel, a set of cells were treated with Lipofectamine
without siRNA and used as control (CTL). After 7 h, 1 ml of RPMI
medium containing 20% FBS and 22.2 mM glucose was added to the
culture containing siRNAs and Lipofectamine (final concentration of
FBS and glucose was 10% and 11.1 mM, respectively). Thereafter,
the cells were allowed to grow for 60 h in RPMI medium (11.1 mM
glucose and 10% FBS), which was replaced every 24 h. After this
period, cells were treated with DEX for 12 h, unless otherwise stated.
Cell proliferation. Cell proliferation was assessed by measuring
BrdU incorporation into DNA using a commercial kit (cat. no. 2750;
Millipore), as described previously (35). Briefly, 4  104 MIN6 or
RINm5F cells were seeded in 96-well plates and allowed to attach
overnight in growth medium. MIN6 cells were transfected with
si-MKP-1, as described above. Twenty-four hours later, the medium
was replaced by low-serum medium (0.1% FBS) containing DEX
(100 nM) or not. DEX treatment was carried out for 72 h, and BrdU
was added to the medium 4 h prior to the end of the treatment.
RINm5F cells were treated for 3 days with DEX (100 nM), PRL (500
ng/ml), or the combination of DEX and PRL in low-serum medium
(0.1% FBS). One well of each condition (from both MIN6 and
RINm5F cells) was kept without BrdU to be used as background.
Next, cells were incubated for 1 h at RT with anti-BrdU antibody and
sequentially incubated with goat anti-mouse IgG antibody conjugated
with peroxidase. Afterward, cells were washed and incubated with
tetramethylbenzidine peroxidase substrate, and absorbance of 450 nm
light was acquired in a spectrophotometer. Blank (tetramethylbenzi-
dine peroxidase substrate) was subtracted from all readings and the
respective background absorbance was discounted from each condi-
tion.
Western blotting. Isolated islets and cultured cells were homoge-
nized in 100 l of solubilization buffer and processed for protein
extraction and Western blot, as described previously (5). After cen-
trifugation, equal amounts of protein were resolved in SDS-PAGE and
transferred to nitrocellulose membranes. Detection using specific
antibodies, horseradish peroxidase-conjugated secondary antibodies,
and luminol solution was performed as described previously (5).
Densitometry was performed using the Scion Image software (Scion).
RNA extraction and real-time PCR. Cells and isolated islets were
harvested in Trizol reagent (Carlsbad, CA) and processed for total
RNA extraction; cDNA synthesis was performed with 2 g of total
RNA. Real-time PCR primers’ sequences and amplification condi-
tions are MKP-1 sense 5=-CAAGAGCATCCCTGTGGAGGAC-3= and
antisense 5=-AGGTAAGCAAGGCAGATGGTGG-3=, 56°C; MKP-
2 sense 5=-GAAGAAACGGGTGAGGCTGGAG-3= and antisense
5=-GCTGAAGACGAACTGCGAGGTG-3=, 60°C; MKP-3 sense
5=-TGTCCTGGTGCATTGCTTGG-3= and antisense 5=-GGTGAAG-
TAGAGCTGCTGTGCG-3=, 57°C; and RPL37a sense 5=-CAAGAAG-
GTCGGGATCGTCG-3= and antisense 5=-ACCAGGCAAGTCTCA-
GGAGGTG-3=. Relative expression levels were analyzed using the
2CT method with RPL37a as internal control.
ChIP assay. A group of 500 freshly isolated islets were processed
using buffers and reagents from the EZ ChIP Kit (cat. no. 17371;
Millipore) according to manufacturer’s instructions. Briefly, islets
were fixed in Hanks’ buffer containing 1% formaldehyde for 10 min
at room temperature and transferred to lysis buffer. DNA was sheared
to fragments of200–1,000 bp by applying eight bursts of sonication
(40% of power, 10 s each). Samples were diluted in dilution buffer
and precleared for 1 h at 4°C with protein A-sepharose (50% slurry)
saturated with salmon sperm DNA. An aliquot of 10 l was collected
as “input.” The remaining supernatants were submitted to immuno-
precipitation with protein A-sepharose saturated with salmon sperm
DNA and 2 g of anti-GR antibody. In parallel, one sample was
incubated only with protein A-sepharose to generate the negative
control (no-AB). Sepharose pellets were then washed with buffers
provided in the kit and treated with elution buffer (1% SDS and 0.1 M
NaHCO3). Supernatants were submitted to cross-link reversal and
RNAse A treatment. DNA was purified using phenol-chloroform and
resuspended in 20 l of sterile ddH2O. DNA samples were amplified
for detection of the MKP-1 promoter. A 138-bp fragment correspond-
ing to nucleotides 118 to 20 of the rat MKP-1 gene was amplified
by real-time PCR. The sequences of the primers were sense
5=-AGCCAGATTAGGATCAGCGAGCAC-3= and antisense 5=-GAT-
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GCCCACCTCCATCACCATG-3=, 57°C. To check the primers’ speci-
ficity (by estimated product length), an aliquot of the reaction products
was resolved in EtBr-agarose gel. GC receptor (GR) binding was calcu-
lated after normalization by the input of each sample.
Statistical analysis. Results are presented as means  SE. Com-
parisons were performed by using unpaired Student’s t-test or one-
way ANOVA, followed by Tukey-Kramer post hoc testing when
appropriate (INStat; GraphPad Software, San Diego, CA). P values
	0.05 indicate a significant difference.
RESULTS
ERK1/2 phosphorylation and MKP expression in pancreatic
islet postpregnancy. Protein content of ERK1/2 was not
altered in pancreatic islets from P19 and L3 rats (Fig. 1A).
On the other hand, ERK1/2 tyrosine phosphorylation (phos-
pho-ERK1/2) was increased in islets from P19 rats (1.92 
0.10-fold for P19 compared with CTL). The higher level of
phospho-ERK1/2 was temporally limited to pregnancy. In
pancreatic islets from L3 rats, phospho-ERK1/2 was lower
than in CTL rats (0.58  0.10-fold; Fig. 1B).
MKP-1, MKP-2, and MKP-3 expression were evaluated in
islets from CTL and L3 rats. MKP-1 mRNA content was
significantly augmented (1.17  0.05-fold of CTL; Fig. 1C),
whereas MKP-2 was diminished (0.70  0.09-fold of CTL;
Fig. 1D). MKP-3 did not change in pancreatic islets from L3
rats (Fig. 1E).
GCs are known to stimulate MKP-1 expression through
direct activation of the GR (14). We next demonstrate that in
vivo binding of GR to MKP-1 promoter is increased in islets
from L3 rats (2.51  0.43-fold of CTL islets; Fig. 1F).
Increased GR binding to MKP-1 promoter correlates with
increased MKP-1 protein content in islets from L3 rats (1.50
0.13-fold of CTL islets; Fig. 1G).
Fig. 1. Relationship between ERK1/2 tyrosin (Tyr) phos-
phorylation and MAPK phosphatase (MKP)-1 expression in
pancreatic islets isolated from pregnant and lactating rats.
Pancreatic islets were isolated from virgin [control (CTL)]
rats and rats on the 19th day of pregnancy (P19) and on the
3rd day of lactation (L3). Isolated islets were processed for
protein extraction and Western blot detection of ERK1/2 (A)
and Tyr-phosphorylated ERK1/2 (pERK1/2; B), with the
latter expressed as the ratio between pERK and total ERK1/2
content. Islets were also processed for RNA extraction and
used for cDNA synthesis and real-time PCR analysis of
MKP-1 (C), MKP-2 (D), and MKP-3 (E) mRNA content.
Binding of glucocorticoid receptor (GR) to MKP-1 gene was
evaluated by the amplification of MKP-1 promoter region
from DNA immunoprecipitated [chromatin immunoprecipi-
tation (ChIP)] with anti-GR
 antibody (see MATERIALS AND
METHODS for details). DNA was also amplified from total
DNA (input) from each sample and from a negative control
(no-AB). F: PCR products from each sample were normal-
ized by the respective input. G: extracted proteins were also
used for Western blot detection of MKP-1 and -actin, with
the latter used as inner control. Data are shown as means 
SE. *P 	 0.05 vs. CTL; &P 	 0.05 vs. P19 (n  3–10 for
Western blot, 4–8 for RT-PCR, and 3 for ChIP assay). AU,
arbitrary units.
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Inhibition of ERK1/2 phosphorylation by GCs in RINm5F
cells correlates with the upregulation of MKP-1. To further
demonstrate the role of GCs in the regulation of MKP in
pancreatic -cells, we next evaluated MKP’s expression in
RINm5F cells treated with DEX. RNA levels in these cells
followed the same pattern of that found in islets from L3 rats.
Cells treated with DEX displayed an increase of MKP-1
(1.33  0.03-fold; Fig. 2A) and a decrease of MKP-2 (0.70 
0.08-fold; Fig. 2B) compared with vehicle-treated cells. Also,
MKP-3 expression did not change after DEX treatment (Fig.
2C). Because MKP-1 was consistently augmented in both islets
from L3 rats and DEX-treated RINm5F cells, we performed
the next experiments to explore the putative role of MKP-1
expression and ERK1/2 activity relationship in -cells. Thus,
the kinetics of phospho-ERK1/2 levels and MKP-1 expression
in RINm5F under DEX treatment was evaluated. DEX induced
a rapid and transient increase in phospho-ERK1/2, followed by
a gradual decrease after 2 h of treatment (0.67  0.25- to
0.35 0.45-fold of CTL for 2- and 8-h treatment, respectively;
Fig. 2D). Neither ERK1/2 nor -actin contents were changed
by DEX. MKP-1 protein content drastically increased after
short-term treatment, which was maintained throughout the
treatment period (12.81  0.45- to 10.00  0.32-fold of CTL
for 0.5- and 8-h treatment, respectively; Fig. 2E).
In the next set of experiments, we evaluated the concentration
of DEX that causes both a decrease in phospho-ERK1/2 and an
increase in MKP-1 protein content. Figure 3 shows that 50 nM
DEX was sufficient to inhibit phospho-ERK1/2 (0.48 0.11-fold
compared with vehicle alone; Fig. 3A) and stimulate MKP-1
expression (6.24  0.58-fold of CTL; Fig. 3B).
Fig. 2. Time course of ERK1/2 dephosphorylation and
MKP-1 expression induced by dexamethasone (DEX) in
RINm5F cells. RINm5F cells were treated with 100 nM
DEX for 12 h and then processed for RNA extraction and
cDNA synthesis; CTL cells were treated with vehicle.
Samples were used for real-time PCR analysis of MKP-1
(A), MKP-2 (B), and MKP-3 (C). Another set of cells was
subjected to DEX treatment during intervals that ranged
from 15 min to 8 h. These cells were used for protein
extraction and Western blot detection of total ERK1/2,
pERK1/2 (D), and MKP-1 and -actin content (E). Results
are expressed as MKP/RPL37a ratio for MKP mRNA
content, pERK1/2/ERK1/2 ratio for ERK1/2 phosphoryla-
tion, and MKP-1/-actin for MKP-1 expression. Data are
shown as means  SE. *P 	 0.05 vs. CTL (n  2–4 for
RT-PCR and 3 for Western blot).
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It was previously postulated that DEX at the concentration
of 100 nM is equivalent to the maternal endogenous GCs at the
end of pregnancy (44). To mimic the physiological milieu of
pregnancy/lactation transition, the following experiments were
performed with 100 nM DEX.
ERK1/2 inactivation by DEX depends on the expression of a
phosphatase. To determine whether DEX-dependent ERK1/2
dephosphorylation was mediated by the upregulation of a
phosphatase, we used two distinct protocols: RINm5F cells
treated with 1) the inhibitor of protein synthesis cycloheximide
and 2) the inhibitor of protein tyrosine phosphatase sodium
orthovanadate. DEX-mediated ERK1/2 dephosphorylation (0.52 
0.19-fold of CTL cells) was prevented by treatment with
cycloheximide (Fig. 4A). Orthovanadate produced similar re-
sults, thus suppressing DEX-induced decrease in phospho-
ERK1/2. When orthovanadate was added to the medium, with
or without DEX, phospho-ERK1/2 was higher than that found
in CTL (5.06  0.14- and 5.19  0.26-fold of CTL cells; Fig.
4B). This result further indicates that basal phospho-ERK1/2 is
maintained by a constitutive phosphatase activity that is stim-
ulated by DEX.
As previously shown herein, MKP-1 protein content was
significantly increased by DEX treatment (8.46  0.36-fold of
vehicle-treated cells). The presence of cycloheximide in the
culture medium abrogated DEX-induced MKP-1 expression,
which suggests that ERK1/2 inactivation is secondary to the
increased MKP-1 expression (Fig. 4C). In addition, cell treat-
ment with orthovanadate did not change MKP-1 content. In
these cells, DEX increased MKP-1 content (3.10  0.33-fold
of vehicle-treated cells), even in the presence of orthovanadate
(2.85  0.49-fold of orthovanadate-treated cells) (Fig. 4D).
ERK1/2 inactivation by DEX depends on the stimulation of
MKP-1 expression. Before the evaluation of the effects of
MKP-1 knockdown with siRNA (si-MKP-1), we brought about
again some key experiments using the mouse insulinoma cell
lineage MIN6, which is known to express MKP-1 (45). Figure 5
shows that the effects of DEX in RINm5F cells were repro-
duced in MIN6 cells. Phospho-ERK1/2 was reduced 0.58 
0.17-fold (Fig. 5A), whereas MKP-1 protein content increased
3.52 0.33-fold compared with vehicle-treated cells (Fig. 5B).
Transfection of MIN6 cells with siRNA targeted to MKP-1
led to the reduction of almost 60% of MKP-1 content, even in
the presence of DEX (Fig. 5D). -Actin protein content was
not affected by the transfection (Fig. 5C). In MIN6 cells,
phospho-ERK1/2 was for orthovanadate (Fig. 5E) and si-
MKP-1 (Fig. 5F) 3.02  0.07- and 2.62  0.38-fold, respec-
tively, higher than DEX-treated cells. The combination of DEX
with either orthovanadate or si-MKP-1 did not result in any
decrease of phospho-ERK1/2. Thus, the values of phospho-
ERK1/2 obtained by the combination of DEX and orthovana-
date or DEX and si-MKP-1 were the same as orthovanadate
and si-MKP-1 alone, respectively.
Involvement of MKP-1 expression, DEX, and PRL on -cell
proliferation. In parallel with phospho-ERK 1/2, DEX treat-
ment reduced MIN6 cell proliferation (0.48  0.12-fold of
vehicle-treated cells). MKP-1 knockdown experiments re-
vealed that the reduction of MKP-1 protein content by itself
did not increase the proliferation rate of MIN6 cells. How-
ever, MKP-1 knockdown abolished the reduction in prolif-
eration induced by DEX in such a way that proliferation rate
of cells transfected with si-MKP-1 and treated with DEX
was not different from si-MKP-1 cells (Fig. 6A). We have
also measured -cell proliferation under PRL and DEX
treatment. In Fig. 6B, we show that PRL increased cell
proliferation (1.21  0.06-fold of CTL). DEX reduced
-cell proliferation in either the absence or presence of PRL
(0.79  0.09- and 0.81  0.06-fold of CTL, respectively).
In parallel with the increased -cell proliferation, PRL
induced an increase in phospho-ERK1/2 (1.31  0.1-fold of
CTL; Fig. 6C). DEX reduced phospho-ERK1/2 irrespective
of the presence of PRL (0.54  0.15-fold of CTL).
DISCUSSION
It is well accepted that most of the changes comprising
maternal pancreatic -cell adaptation to pregnancy, including
increased proliferation, result primarily from placental lacto-
gen and PRL action (1, 24). The contribution of gestational
hormones on -cell adaptation to pregnancy is highlighted by
the demonstration that, even when the increased demand for
insulin is compensated by exogenous insulin, changes in islet
function characteristic of gestation still occur (36). However,
Fig. 3. Dose-response curve of ERK1/2 dephosphorylation and MKP-1
expression to DEX in RINm5F cells. RINm5F cells were treated with 10,
50, 100, 300, and 3,000 nM DEX for 2 h. Afterward, cells were processed for
protein extraction and Western blot detection of total ERK1/2, pERK1/2 (A), and
MKP-1 and -actin content (B). Results are expressed as pERK1/2/ERK1/2 ratio for
ERK1/2 phosphorylation and MKP-1/-actin for MKP-1 expression. Data are shown
as means  SE. *P 	 0.05 vs. CTL (n  2–5).
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the increases in both insulin secretion and -cell proliferation
are time-limited events that resume the nonpregnant features
just after the delivery (5, 38). It is likely that the reduction of
intracellular calcium stores and SERCA2 expression in pan-
creatic islets mediate the decrease of maternal insulin secretion
just after delivery (5, 25). However, the precise mechanism by
which the pancreatic -cell switches from a high to a low
proliferative status is much less comprehended. Our results
show that the dynamics of ERK1/2 phosphorylation are in
temporal accordance with the pattern of maternal -cell pro-
liferation during the peripartum, as described by Scaglia et al.
(38). This temporal coincidence suggests a basic role of
ERK1/2 in this adaptation and prompted us to investigate the
mechanism involved in ERK1/2 dephosphorylation at the post-
partum.
ERK1/2 signaling activation is a bona fide requirement for
cell proliferation (33). In islets and -cell lines, extracellular
signals such as GLP-1 (8), islet neogenesis-associated protein
(7), IGF-I (21), and PRL (2) are able to acutely induce ERK1/2
phosphorylation. Because all of these signals are strong mito-
genic factors, it is likely that increased ERK1/2 phosphoryla-
tion mediates -cell growth during pregnancy.
In contrast to its activation, ERK1/2 is negatively regulated
by DUSP, also known as MKP (19). In osteoblasts and smooth
muscle cells, increased MKP-1 expression has been shown to
target ERK1/2 dephosphorylation (18, 23, 30). Accordingly,
our study demonstrates that ERK1/2 dephosphorylation found
in islets of L3 rats correlates with increased MKP-1 expression.
Data accumulated thus far suggest that endogenous GCs
oppose the overall actions of PRL on pancreatic -cell func-
tion, because the simultaneous treatment of isolated islets or
-cell lines with PRL and DEX resembles the postpregnancy
-cell phenotype. It was already settled that DEX reverses
PRL-induced -cell gain of function by inhibiting insulin
secretion and cell proliferation while increasing apoptosis (39,
44). Accordingly, as shown herein, DEX reduced both ERK1/2
phosphorylation and RINm5F cell proliferation, even in the
presence of PRL.
GCs are known to reduce proliferation in a variety of cells,
including smooth muscle (20), lymphoid (40), bone (23), and
pancreatic -cells (6). As such, GCs can modulate the activity
and/or expression of various kinases and phosphatases, thus
affecting the proliferative action of mitogenic signals. It has
been shown that GC antiproliferative action correlates with
increased MKP expression (18). Moreover, the inhibition of
ERK1/2 phosphorylation by GC depends on the induction of
MKP-1 expression (23). Corroborating the hypothesis that GCs
favor the reduction of ERK1/2 phosphorylation in maternal
pancreatic -cell after the delivery, we found that the direct
binding of GR to MKP-1 promoter was increased in islets from
L3 rats. To our knowledge, this is the first report showing a
direct binding of GR to a MKP-1 promoter in pancreatic islets.
Fig. 4. Effects of cycloeheximide and orthovanadate on DEX-
dependent ERK1/2 dephosphorylation and MKP-1 expression.
RINm5F cells were pretreated with 1.5 M orthovanadate
(Na2VO4) or 40 g/ml cycloheximide 1 h prior to DEX treat-
ment (100 nM for 2 h). CTL cells were treated with vehicle.
Cells were processed for protein extraction and Western blot
detection of ERK1/2, pERK1/2, MKP-1, and -actin (inner
control). Variations of pERK1/2 and total ERK1/2 content
(representative blots), as well as pERK1/2/ERK1/2 ratio
(graphs), induced by DEX were calculated under cycloheximide
(A) and Na2VO4 (B) pretreatment. Membranes were also probed
for detection of MKP-1 and -actin. C and D: representative
blots of MKP-1 and -actin and MKP-1/-actin ratio of cyclo-
heximide- and Na2VO4-treated cells, respectively, are shown.
Data are expressed as means  SE. *P 	 0.05 vs. CT; n  2–4
for RT-PCR and 3 for Western blot.
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Importantly, GC-mediated MKP-1 expression has already been
demonstrated to result in a direct binding of the GR to GC-
responsive elements within the MKP-1 promoter in other cell
types (15, 26). In accordance, the use of RU-486, an antagonist
of GR, inhibited DEX-induced MKP-1 expression (26).
To strengthen the interplay among GC, MKP-1, ERK1/2
activity, and -cell proliferation, we next moved on to a series
of experiments using RINm5F and MIN6 cells. Our data show
that MKP-1 expression correlates with DEX-induced ERK1/2
dephosphorylation, reaching maximal effect after 2-h treat-
ment. Also, the repression of ERK1/2 activation and the
increase in MKP-1 content induced by DEX are fully pre-
vented by the treatment with the protein synthesis inhibitor
cyclohexemide. This result shows that the effect of GC on
MKP-1 regulation in pancreatic -cell may be mediated ex-
clusively by transcriptional regulation rather than posttran-
scriptional events. On the other hand, DEX-induced increase in
MKP-1 content in RBL-2H3 cells was demonstrated to be
mediated by both transcriptional and posttranscriptional regu-
lation (26). Our results showing that the reduction of ERK1/2
phosphorylation mediated by DEX in pancreatic -cell was
inhibited by sodium orthovanatade, an unspecific phosphatase
inhibitor, further suggested a crucial role for the increase in
MKP-1 in this regulation.
We also observed a transient increase in ERK1/2 phosphor-
ylation, peaking at 30 min of DEX stimulation. This transitory
effect was followed by a significant decrease in ERK1/2
phosphorylation, reaching levels as low as one-half of basal
Fig. 5. Effects of MKP-1 knockdown on DEX-
dependent ERK1/2 dephosphorylation and MKP-1
expression in MIN6 cells. RINm5F and MIN6
cells were treated with DEX (100 nM for 6 h).
CTL cells were treated with vehicle. Cells were
processed for protein extraction and Western blot
detection of total ERK1/2, pERK1/2 (A), and
MKP-1 and -actin content (B). Results are ex-
pressed as pERK1/2/ERK1/2 ratio for ERK1/2
phosphorylation and MKP-1/-actin for MKP-1
expression. MIN6 cells were transfected with
siRNA targeted to MKP-1 (si-MKP-1) or a scram-
bled control (si-CTL). In parallel, a set of cells was
treated only with transfection reagents. After
transfection, these cells were subjected to protein
extraction and Western blot detection of MKP-1
and -actin content (C); the results are expressed
as MKP-1/-actin (D). MIN6 cells were treated
with 1.5 M orthovanadate (Na2VO4; E) or trans-
fected with si-MKP-1 (F) prior to treatment with
DEX (100 nM for 2 h). Next, cells were subjected to
protein extraction and Western blot detection of total
ERK1/2 and pERK1/2; results are expressed as
pERK1/2/ERK1/2 ratio. Data are expressed as
means SE. *P	 0.05 vs. CTL; &P	 0.05 vs. DEX
(n  4–8).
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values. We do not know if this event has any physiological
relevance in -cells chronically exposed to GCs. Interestingly,
DEX enhanced ERK1/2 phosphorylation at times up to 20 min
in the kidney cell line HK-2, which was correlated to a
protective effect against kidney injury, probably by a mecha-
nism independent of transcriptional activity (29). Of note, rapid
stimulation of MKP-1 and MKP-3 expression was described to
be mediated by ERK1/2 activation, resulting in a negative
feedback over this signaling pathway (17, 40). Therefore, it is
possible that the rapid and transient stimulation of ERK1/2
phosphorylation by DEX found by us (15 min after the begin-
ning of treatment) in RINm5F cells would play a role in the
induction of MKP-1 (30 min after the beginning of treatment)
and then in the long-term ERK1/2 dephosphorylation. Trans-
posing this interpretation to our in vivo results, it is possible
that the increase in ERK1/2 phosphorylation found in islets of
pregnant rats contributes to the increased MKP-1 expression
and decreased ERK1/2 phosphorylation in islets of early lac-
tating mothers.
Because ERK1/2 phosphorylation is induced by a plethora
of signals, the participation of other factors in the increased
phospho-ERK1/2 in late pregnancy must not be ruled out. It is
well known that circulating levels of lipids increase in the last
third of gestation (22). In addressing this issue, Brelje et al.
(10) have demonstrated that palmitate (0.4 mM), combined or
not with PRL, increases proliferation of neonatal islets cultured
for 4 and 8 days. On the basis of these results, the authors
suggested that fatty acids may also contribute to the large
increase in -cell mass. Indeed, it has been shown recently that
palmitate (0.5 mM) increases ERK1/2 phosphorylation in
MIN6N8 cells chronically exposed (48 h) to the fatty acid (28).
We next used siRNA, attempting to specifically inhibit the
rise in MKP-1 content induced by DEX. Knockdown of
MKP-1 resulted in the blockade of DEX-induced ERK1/2
dephosphorylation, pointing out the role of this phosphatase in
DEX modulation of ERK1/2 signaling in the pancreatic -cell.
In a recent review, the several isoforms of MKP already
described (i.e., MKP-1, MKP-2, MKP-3, and MKPx) have
been related to preferential targets among the MAPK proteins
(37). In this sense, MKP-1 is generically linked to a preferen-
tial dephosphorylation of p38 and JNK but is also able to
dephosphorylate ERK1/2. However, MKP-2, MKP-3, and
MKPx show high affinity for ERK1/2 and less for p38 and JNK
(37). Despite this general preference for its substrate, MKP
phosphatase activity seems to be highly cell type and context
specific. For instance, MKP-1 inactivated ERK2, JNK2, and
p38 equally, and MKP-2 was unable to inactivate p38 in HeLa,
NIH3T3, and COS cells (13). Also, the ability of DEX in
inhibit IL-1- and granulocyte macrophage colony-stimulating
factor-induced ERK1/2 phosphorylation in human bronchial
epithelial cells was highly dependent on induction of MKP-1
expression (34). Therefore, we hypothesize that increased
Fig. 6. Effects of MKP-1 knockdown, DEX, and prolactin
(PRL) on pancreatic -cell proliferation. MIN6 cells were
transfected with siRNA targeted to MKP-1 (si-MKP-1) or
treated only with transfection reagent. The next day, at the
beginning of transfection, medium was changed, and cells
were treated with DEX (100 nM) or vehicle for 72 h. RINm5F
cells were also treated for 72 h with DEX (100 nM), PRL
(500 ng/ml), or the combination of both. Treatments were
carried out in medium with 0.1% FBS. After treatments,
MIN6 (A) and RINm5F (B) cells were processed for bro-
modeoxyurudine detection incorporation into newly synthe-
sized DNA. Results are expressed as proliferation rate (which
was defined as the absorbance of cells at each condition
subtracted from their respective background). RINm5F cells
were also processed for Western blot detection of ERK1/2
and pERK1/2; results are expressed as pERK1/2/ERK1/2
ratio. Data are shown as means  SE. *P 	 0.001 vs. CTL,
si-MKP-1, and si-MKP-1  DEX; &P 	 0.05 vs. PRL (n 
6 –18 for proliferation and 8 –10 for Western blot).
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MKP-1 determines reduced ERK1/2 phosphorylation in pan-
creatic islets from L3 rats and in pancreatic -cells treated with
DEX. Our findings showing increased MKP2 and unaltered
MKP3 in both of these situations further corroborate this
proposition.
The functional relevance of our findings is evidenced by the
experiments measuring incorporation of BrdU to DNA as an
estimative of cell proliferation. We found that DEX-induced
reduction in proliferation of MIN6 cells was completely abol-
ished by MKP-1 knockdown. In accordance with these results,
DEX was already demonstrated to reduce osteoblast prolifer-
ation secondary to induction of MKP-1 and reduction of
ERK1/2 phosphorylation (18, 23).
Altogether, the new findings presented herein can be sum-
marized as follows. First, the temporal changes of ERK1/2
phosphorylation in pancreatic islets from rats at the end of
pregnancy and at the beginning of lactation coincide with
changes in MKP-1 expression. The increase in MKP-1 proba-
bly results from GC action, because GR binding to MKP-1
promoter is increased in islets from L3 rats. Second, experi-
ments with -cell lines show that DEX-induced dephosphory-
lation of ERK1/2 and reduced proliferation rate are highly
dependent on the induction of MKP-1 expression.
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